Common Cosentyx Side Effects
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, most often causes upper respiratory tract infections (14-20% of patients), diarrhea (up to 11%), and nasopharyngitis.[1][2] Other frequent reactions include oral herpes (9%), rhinitis (5-8%), and mild injection-site reactions like redness or itching (3-7%).[1]
Serious Side Effects Patients Report
Severe risks include increased infection susceptibility, such as tuberculosis reactivation or invasive fungal infections, reported in clinical trials and post-marketing data.[1][2] Inflammatory bowel disease flares (Crohn's or ulcerative colitis) occur in 1-2% of cases, sometimes leading to discontinuation.[1] Rare hypersensitivity reactions, including anaphylaxis, and new-onset or worsening IBD have prompted FDA warnings.[2] Neutropenia and elevated liver enzymes appear in under 1% but require monitoring.[1]
Side Effects by Condition Treated
In psoriasis trials, respiratory infections topped lists at 18%, with headache (7%) and urticaria (4%) common.[1] Psoriatic arthritis patients saw more diarrhea (11%) and tendon inflammation.[2] Ankylosing spondylitis data mirrors this, adding back pain exacerbations in 5-10%.[1] Pediatric use for juvenile idiopathic arthritis reports similar profiles, with growth monitoring advised.[2]
How Long Do Side Effects Last?
Most mild effects like infections or injection-site issues resolve within days to weeks.[1] Serious infections may persist or require hospitalization, while IBD flares can last months without intervention.[2] Long-term studies (up to 5 years) show sustained infection risk without cumulative worsening.[1]
Infections and Immunosuppression Risks
Cosentyx raises opportunistic infection odds by blocking IL-17, with trial rates 2-3 times higher than placebo.[1] Screen for latent TB before starting; live vaccines are contraindicated.[2] Post-approval reports include cellulitis, pneumonia, and sepsis in vulnerable patients.[1]
Who Gets Side Effects Most?
Elderly patients and those with comorbidities face higher infection rates (up to 25%).[1] Concomitant steroids or prior biologics increase IBD risk.[2] No major sex differences, but women report more injection-site reactions.[1]
Managing and Reporting Side Effects
Use pre-filled syringes or autoinjectors to minimize skin reactions; rotate sites.[1] Report severe symptoms to FDA MedWatch. Discontinuation reverses most effects within months.[2]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab